Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
-
+
JCSE 01.10 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
10:05 - 10:20 | Presenter: Songtao Xu | Author(s): W. Zhong, Y. Zhang, W. Mao, L. Wu, Y. Shen, Y. Liu, C. Chen, Ying Cheng, L. Xu, J. Wang, K. Fei, X. Li, J. Li, C. Huang, Z. Liu, S. Xu, K. Chen, S. Xu, L. Liu, P. Yu, B. Wang, H. Ma, H. Yan, X. Yang, Yi-Long Wu, Q. Wang
- Abstract
Loading...
-
+
MA 05 - Immuno-Oncology: Novel Biomarker Candidates
- 15:45 - 17:30
- 10/16/2017
- Location: Room 303 + 304
- Type: Mini Oral
- Track: Immunology and Immunotherapy
- Moderators:Yoichi Nakanishi, P. Mitchell
-
+
MA 05.07 - Whole Body PD-1 and PD-L1 PET in Pts with NSCLC
16:25 - 16:30 | Presenter: J. De Langen | Author(s): Anna-Larissa Nadia Niemeijer, Egbert F Smit, G.A. Van Dongen, A.D. Windhorst, M.C. Huisman, N. Hendrikse, I. Bahce, D.K. Lueng, R.A. Smith, W. Hayes, L.M. Wilson, S.J. Bonacorsi, D.J. Donnelly, P.E. Morin, A. Poot, D.J. Vugts, Erik Thunnissen
- Abstract
Loading...
-
+
P2.01 - Advanced NSCLC
- 09:00 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P2.02 - Biology/Pathology
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
-
+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P2.03-047 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
09:30 - 09:30 | Presenter: Songtao Xu | Author(s): W. Zhong, Y. Zhang, W. Mao, L. Wu, Y. Shen, Y. Liu, C. Chen, Ying Cheng, L. Xu, J. Wang, K. Fei, X. Li, J. Li, C. Huang, Z. Liu, S. Xu, K. Chen, S. Xu, L. Liu, P. Yu, B. Wang, H. Ma, H. Yan, X. Yang, Yi-Long Wu, Q. Wang
- Abstract
Loading...
-
+
MA 09 - The Current Status of Radiation Oncology
- 11:00 - 12:30
- 10/17/2017
- Location: Room 316
- Type: Mini Oral
- Track: Locally Advanced NSCLC
- Moderators:Tomoki Kimura, Yong Chan Ahn
-
+
MA 09.08 - Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1
11:55 - 12:00 | Presenter: Jarushka Naidoo | Author(s): K.R. Voong, S.Z. Hazell, C. Hu, J. Hayman, R. Hales, K.A. Marrone, C.L. Hann, David S Ettinger, J.L. Feliciano, V. Rowe, R.J. Kelly, Julie R Brahmer, Patrick M Forde
- Abstract
Loading...
-
+
MA 11 - Emerging Diagnostic/Biomarkers in NSCLC
- 11:00 - 12:30
- 10/17/2017
- Location: Room 313 + 314
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:M.I. Abdul Wahid, Martin Reck
-
+
MA 11.03 - Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
11:10 - 11:15 | Presenter: Jie Wang | Author(s): Ying Cheng, Yi-Long Wu, T. An, H. Gao, K. Wang, Qing Zhou, Y. Hu, Yong Song, C. Ding, F. Peng, L. Liang, Y. Hu, C. Huang, Caicun Zhou, Y. Shi, Li Zhang, X. Ye, Y. Sun
- Abstract
Loading...
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-026 - Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Martin Schuler | Author(s): James Chih-Hsin Yang, Lecia V Sequist, Yi-Long Wu, Caicun Zhou, S.L. Geater, Tony SK Mok, E. Tan, C. Hu, Nobuyuki Yamamoto, J. Feng, Kenneth Obyrne, Shun Lu, Vera Hirsh, Y. Huang, S. Ellis, C. Samuelsen, A. Märten, J. Fan, Keunchil Park, Luis Paz-Ares
- Abstract
Loading... -
+
- Abstract
Loading... -
+
P3.01-075 - Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Vera Hirsh | Author(s): E. Tan, Yi-Long Wu, Lecia V Sequist, Caicun Zhou, Martin Schuler, S.L. Geater, Tony SK Mok, C. Hu, Nobuyuki Yamamoto, J. Feng, Kenneth Obyrne, Shun Lu, Y. Huang, M. Sebastian, Isamu Okamoto, N. Dickgreber, R. Shah, M. Palmer, A. Märten, D. Massey, C. Samuelsen, James Chih-Hsin Yang
- Abstract
Loading... -
+
P3.01-084 - Analysis on ALTER0303 Trial: aCECs Level May Correlate with Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC
09:30 - 09:30 | Presenter: Kai Li | Author(s): Z. Liu, J. Wang, Z. Meng, X. Wang, C. Zhang, J. Chen, X. Jiang, L. Wang, L. Lin, X. Zhang, P. Chen, C. Huang, R. Jiang
- Abstract
Loading... -
+
P3.01-087 - Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303
09:30 - 09:30 | Presenter: Kai Li | Author(s): J. Wang, Baohui Han, Y.Z. Zhao, Qiming Wang, L. Zhang, J. Shi, Z. Wang, J. He, Yuankai Shi, Ying Cheng, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, J. Dong, B. Li, Y. Chen, J. Zhou, D. Wang, X. Zhou, Y. Yu, L. Chen, A. Liu, J. Huang, C. Huang, B. Cao, J. Chen, R. Ma, Z. Yu, C. Ding, H. Wang
- Abstract
Loading...
-
+
P3.02 - Biology/Pathology
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
-
+
P3.02-066 - Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Chiara Ambrogio | Author(s): J. Kohler, Z. Zhou, H. Wang, R. Paranal, M. Capelletti, C. Caffarra, S. Li, Q. Lv, S. Gondi, J.C. Hunter, R. Chiarle, D. Santamaría, K.D. Westover, Pasi A Jänne
- Abstract
Loading... -
+
- Abstract
Loading...